BCTXZ
BriaCell Therapeutics Corp.
NASDAQ · Healthcare · Biotechnology · CA
$0.11
+3.99%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- -19.3%
- EPS
- +85.2%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- +100.0%
- EBIT
- +100.0%
- Net income
- -31.1%
- EPS
- +88.9%
- Free cash flow
- -0.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jul 1, 2026